India's Central Drugs Standard Control Organization (CDSCO - equivalent to FDA in the U.S.) grants approval for the sale of four new antimicrobial wound care products based on ABL's patented technology; study results show effectiveness against broad variety of pathogens, accelerated heal times ALPINE, UT, Sept. 17 /PRNewswire-FirstCall/ -- American Biotech Labs (ABL), creator of a new class of products based on the company's patented nano-catalytic SilverSol Technology(TM), today announced that the agency responsible for drug and medical device oversight in India - Central Drugs Standard Control Organization ("CDSCO") has approved four new ABL antimicrobial wound care products for sale in India. CDSCO is the Indian counterpart to the U.S. FDA. The four new antimicrobial wound care products are based on ABL's patented SilverSol Technology and include: a wound wash; a wound disinfectant; an antimicrobial gel; and a patented antimicrobial wound care patch. "This approval by India's primary drug and medical device oversight organization is a significant milestone for these products and for ABL," said William D. Moeller PhD, Chairman of Clifton Mining Company (OTC:CFTNOTC: 21-percentOTC:ownerOTC:ofOTC:ABL). "The approval validates the power and efficacy of our technology for wound care. We believe India will be a large market for these products." "The Indian government has recognized the tremendous potential benefits these products can offer in accelerating heal time and reducing cost and complications of infection - particularly in health care facilities," said Keith Moeller, a Managing Director over sales and marketing for ABL. "We are honored to be on the forefront of technology that can provide improved healthcare outcomes to people around the globe." ABL will market and sell its new product line in India, consistently identified as one of the world's largest and most dynamic markets, through its partner Viridis Biopharma, headquartered in Mumbai, India. Viridis is a supplier of bio-pharma products and medical devices throughout the Indian subcontinent. ABL is also currently awaiting 510K regulatory approvals for wound care products in the United States and Singapore. Separately, recently-completed rigorous efficacy testing of these products has shown strong results against a broad variety of resistant microbes, including the multi-drug-resistant staph infection MRSA (methycillin-resistant staph aureus), VRE (vancomycin-resistant enterococci) and numerous other pathogens. About American Biotech Labs American Biotech Labs (ABL; http://www.americanbiotechlabs.com/), founded in 1998, utilizes patented processes and SilverSol Technology(TM) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the U.S. EPA as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings. The company's products have been the subject of a number of peer-reviewed articles in professional journals and are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands, and through a variety of private labels. DATASOURCE: Clifton Mining Company CONTACT: Dr. Ken Friedman, President at (303) 642-0659; Keith Moeller, Vice President at (801) 756-1414 or see the websites at http://www.cliftonmining.com/ and http://www.americanbiotechlabs.com/

Copyright